Vaccine has been approved in China, Mexico, Pakistan, Hungary and Chile
Provides timely clinical protection for adults aged 18 and above, including those over 60
TIANJIN, China, May 24, 2021 /PRNewswire/ CanSino Biologics Inc. ( CanSinoBIO ) (SHSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™), has been granted a Good Manufacturing Practice ( GMP ) certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI). The certification was issued on May 21, 2021 after a thorough inspection of CanSinoBIO s production of Convidecia™.
The GMP certificate recognizes that CanSinoBIO s manufacturing facilities and quality control system comply with the high production standards and guidelines required by the European Union ( EU ). The EU GMP certification is required to import COVID-19 vaccines into the European Union and is regarded as a recognition of leading ind
CanSinoBIO Gets GMP Certificate for Its Vaccine to Enter European Countries
Hungarian National Institute of Pharmacy and Nutrition (OGYEI) has granted a Good Manufacturing Practice (GMP) certificate to CanSino Biologics, a Chinese vaccine manufacturer founded in 2009, for its COVID-19 vaccine known as Convidecia.
According to details, OGYEI issued the GMP certificate to CanSinoBIO on 21 May after a comprehensive inspection of CanSinoBIO’s manufacturing of Convidecia.
ALSO READ
The GMP certificate by an EU member shows that CanSinoBIO’s manufacturing facilities and quality control system are in line with high production standards and guidelines laid down by the EU.
The EU’s GMP certificate is required to import COVID-19 vaccines into Europe which indicates that CanSinoBIO is ready to enter more markets in Europe and globally.
Share this article
Share this article
Continues to boost production capacity to meet increasing demand
Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions
95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination
Vaccines provide timely mass protection for adults aged 18 and above, including those over 60
TIANJIN, China, March 22, 2021 /PRNewswire/ CanSinoBIO Biologics Inc. ( CanSinoBIO ) (HKEX: 06185) today announced that the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™). The approval is based on the vaccine s interim results for Phase III clinical trial and marks the first approval of Convidecia™ in an European Union member state.
Chile grants EUA to CanSinoBIO’s single-dose Covid-19 vaccine
Most Read
Most Recent
Most Read
Most Recent 9 April 2021 (Last Updated April 9th, 2021 11:39)
The Instituto de Salud Pública de Chile (ISP) has granted Emergency Use Authorization (EUA) to China-based company CanSino Biologics’ (CanSinoBIO) novel recombinant adenovirus type 5 vector Covid-19 vaccine Convidecia (Ad5-nCoV).
Convidecia is the first single-dose vaccine to receive emergency use approval in Chile. Credit: CanSinoBIO.
Share Article
The Instituto de Salud Pública de Chile (ISP) has granted Emergency Use Authorization (EUA) to China-based company CanSino Biologics’ (CanSinoBIO) novel recombinant adenovirus type 5 vector Covid-19 vaccine Convidecia (Ad5-nCoV).
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia in Chile finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.